Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:45:45.032Z.
Calculation as of: 2026-10-06T22:45:45.032Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$280.37M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.54M
EV/Sales Ratio
N/A
TTM Avg
5.51x
3Y Avg
58.44x
5Y Avg
51.98x
Market Cap
$282.64M
EV/Sales Ratio
0.48x
TTM Avg
2.42x
3Y Avg
2.68x
5Y Avg
2.39x
Market Cap
$284.31M
EV/Sales Ratio
1.04x
TTM Avg
0.84x
3Y Avg
0.87x
5Y Avg
1.56x
Market Cap
$285.42M
EV/Sales Ratio
N/A
TTM Avg
19.43x
3Y Avg
19.05x
5Y Avg
19.05x
Market Cap
$285.55M
EV/Sales Ratio
9.76x
TTM Avg
250.43x
3Y Avg
190.32x
5Y Avg
110.72x
Market Cap
$288.79M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.81M
EV/Sales Ratio
1.11x
TTM Avg
1.48x
3Y Avg
1.04x
5Y Avg
1.35x
Market Cap
$270.80M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $280.37M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | N/A | 5.51x | 58.44x | 51.98x |
| Standard BioTools Inc. (LAB)vs › | $282.64M | 0.48x | 2.42x | 2.68x | 2.39x |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | 1.04x | 0.84x | 0.87x | 1.56x |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | N/A | 19.43x | 19.05x | 19.05x |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | 9.76x | 250.43x | 190.32x | 110.72x |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | 1.11x | 1.48x | 1.04x | 1.35x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
